News from amarin corporation plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 13, 2019, 18:14 ET Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk

Amarin Corporation plc (NASDAQ: AMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication and label...


Mar 18, 2019, 09:00 ET Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa®...


Nov 11, 2018, 10:32 ET Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint

Amarin Corporation plc (NASDAQ: AMRN), announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial,...


May 10, 2011, 03:00 ET Amarin Reports First Quarter 2011 Results

Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results ...


Apr 26, 2011, 08:00 ET Amarin to Present at the Deutsche Bank 26th Annual Healthcare Conference

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John...


Apr 18, 2011, 02:00 ET Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive,...


Apr 05, 2011, 08:00 ET Phase 3 MARINE Trial Data to be Presented in May at the National Lipid Association 2011 Annual Scientific Sessions

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data...


Mar 31, 2011, 07:30 ET Amarin to Present at the 10th Annual Needham Healthcare Conference

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that...


Mar 16, 2011, 06:40 ET Amarin Reports Year-End and Q4 2010 Results

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results ...


Mar 08, 2011, 04:30 ET Amarin to Present at Two Upcoming Investor Conferences

Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in two upcoming investor conferences: the Barclays Capital...


Feb 22, 2011, 08:00 ET Amarin to Present at Two Upcoming Investor Conferences

MYSTIC, Conn. and DUBLIN, Feb 22, 2011 Amarin Corporation plc (Nasdaq: AMRN) today announced that members of its senior management team will be...


Feb 07, 2011, 08:00 ET Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference

Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable...


Feb 02, 2011, 06:00 ET Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Paul E....


Jan 31, 2011, 09:00 ET Amarin Provides 2010 Year-End Review to Shareholders

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today issued a special...


Jan 11, 2011, 02:30 ET Amarin Announces Successful Completion of Offering of American Depositary Shares

Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...


Jan 07, 2011, 09:00 ET Amarin Announces Underwriters' Exercise of Over-Allotment Option

Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...


Jan 06, 2011, 09:00 ET Amarin Prices Public Offering of American Depositary Shares

Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...


Jan 05, 2011, 07:30 ET Amarin to Present at the 29th Annual J.P. Morgan Healthcare Conference

Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on...


Jan 05, 2011, 04:50 ET Amarin Announces Proposed Public Offering of American Depositary Shares

Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...


Dec 16, 2010, 07:00 ET Amarin Completes Patient Randomization in Phase 3 ANCHOR Trial

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the...


Dec 03, 2010, 11:00 ET Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference

Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes &...


Nov 29, 2010, 06:00 ET Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive,...


Nov 26, 2010, 04:15 ET Amarin to Host Conference Call at 8:30 a.m. EST on November 29, 2010, to Discuss Top-Line Results of Phase 3 MARINE Study of AMR101 in Patients with Very High Triglycerides

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it...


Nov 18, 2010, 07:00 ET Amarin Corporation Appoints Kristine Peterson to Board of Directors

Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the...


Nov 15, 2010, 07:30 ET Amarin to Present at Lazard Capital Markets Annual Healthcare Conference

Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference...